Pembrolizumab plus concurrent chemoradiation therapy associated with robust antitumor activity in patients with locally advanced, unresectable, stage III non-small cell lung cancer
1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, ...